Adult Antiemetic Management of Chemotherapy-Induced Nausea and Vomiting (CINV)

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

Note: The information provided here applies to standard doses of chemotherapy/biotherapy not requiring stem cell rescue.

RISK ASSESSMENT

Assess for level of patient risk
- Young age
- Female
- Non-alcohol drinker
- Non-steroid user
- History of motion sickness
- Those previously failing conventional antiemetic therapy

Note: These characteristics represent increased risk for CINV; closer monitoring and more frequent reassessment recommended

Determine emetogenicity of chemotherapy/biotherapy (see Appendix A)

Is patient currently nauseated or have risk factors1 for anticipatory nausea/vomiting?

Yes
- Prevention of chemotherapy-induced nausea and vomiting (CINV)

No
- For IV chemotherapy regimens, see Pages 2 and 3
- For PO chemotherapy regimens, see Page 4
- For IV/PO combination chemotherapy, use highest emetogenic agent to determine antiemetics

Pharmacologic interventions:
- Alprazolam 0.5 – 2 mg PO prior to chemotherapy or
- Lorazepam 1 – 2 mg IV or PO prior to chemotherapy

Behavioral therapy – consider referral to Integrative Medicine for:
- Relaxation techniques
- Hypnosis
- Systematic desensitization

Note: Risk factors for anticipatory nausea/vomiting are not clearly defined in the literature, but could broadly be listed as: nausea/vomiting with prior chemotherapy; history of motion sickness; history of emesis during pregnancy or hyperemesis gravidum; female gender.
Adult Antiemetic Management of Chemotherapy-Induced Nausea and Vomiting (CINV)

Prevention of HEC HEC and MEC

IV CHEMOTHERAPY HIGH (HEC) AND MODERATE (MEC) RISK

Prevention of CINV HEC and MEC

<table>
<thead>
<tr>
<th>Prevention of CINV HEC and MEC</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HEC single day ONLY:</strong> Olanzapine, serotonin antagonist (SA), neurokinin-1 antagonist (NKA) (see Page 10)</td>
</tr>
<tr>
<td><strong>HEC or MEC, single day ONLY:</strong> Olanzapine, SA, steroid (see Page 11)</td>
</tr>
<tr>
<td><strong>HEC or MEC, single and multi-day:</strong> SA, NKA, steroid (see Page 12)</td>
</tr>
<tr>
<td><strong>MEC single or multi-day ONLY:</strong> SA, steroid (see Page 13)</td>
</tr>
</tbody>
</table>

For subsequent cycles, see Page 6

**Disclaimer:** This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

HEC = Highly Emetogenic Chemotherapy, MEC = Moderately Emetogenic Chemotherapy

1 See Appendix A for Emetogenic Potential of Chemotherapy/Biotherapy Agents
2 Assess need for histamine H2 antagonist or proton pump inhibitor (PPI) for dyspepsia
3 All SAs are considered therapeutically equivalent when dosed appropriately; see Appendix C (ondansetron preferred)
4 The following features of steroids should be considered in patients with hematologic malignancies prior to prescribing them as part of the antiemetic regimen: a) risk of immunosuppression; b) avoid duplicative therapy (may already be part of chemotherapy regimen); c) inherent activity against hematologic malignancies may mask beneficial effects of chemotherapy in clinical trials. See Appendix C for other safety considerations.
5 Use of steroids is not recommended with immune and/or cellular therapies. See Appendix C for more detail and other safety considerations.
6 May interact with cytochrome P450 enzyme (CYP enzyme); check for drug interactions – see Appendix C
### IV CHEMOTHERAPY

**LOW AND MINIMAL EMETOGENIC RISK**

#### PREVENTION/PROPHYLAXIS

Prior to start of chemotherapy:
- Short-acting SA\(^1\) PO or IV or
- Steroids\(^2\) PO or IV or
- Phenothiazine PO or IV or
- Prokinetic agent PO or IV

*(Note: Order above does not indicate preference. See Appendix C for dosing and scheduling.)*

Prophylactic antiemetics not required prior to the first cycle of chemotherapy

- For breakthrough nausea/vomiting, see Page 5
- For re-assessment/subsequent cycles, see Page 6

---

\(^1\) See Appendix A for Emetogenic Potential of Chemotherapy/Biotherapy Agents

\(^2\) Assess need for histamine H\(_2\) antagonist or proton pump inhibitor (PPI) for dyspepsia

\(^3\) All SAs are considered therapeutically equivalent when dosed appropriately, see Appendix C (ondansetron preferred)

\(^4\) The following features of steroids should be considered in patients with hematologic malignancies prior to prescribing them as part of the antiemetic regimen: a) risk of immunosuppression; b) avoid duplicative therapy, may already be part of chemotherapy regimen; c) inherent activity against hematologic malignancies may mask beneficial effects of chemotherapy in clinical trials. See Appendix C for other safety considerations.

\(^5\) Use of steroids is not recommended with immune and/or cellular therapies. See Appendix C for more detail and other safety considerations.
Adult Antiemetic Management of Chemotherapy-Induced Nausea and Vomiting (CINV)

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

**ORAL CHEMOTHERAPY EMETOGENIC RISK**

**RECOMMENDATION**

**ANTIEMETIC REGIMEN**

**High to Moderate Risk**

- Antiemetic premedications required

**Low to Minimal Risk**

- No routine premedication required
- PRN medications recommended for breakthrough nausea/vomiting

**Prior to start of chemotherapy:**

- Oral short-acting SA

**Patient experiences nausea/vomiting**

- Oral phenothiazine or oral prokinetic agent or oral short-acting SA (Note: order above does not indicate preference)

- For breakthrough nausea/vomiting, see Page 5
- For re-assessment/subsequent cycles, see Page 6

1. Assess need for histamine H₂ antagonist or proton pump inhibitor (PPI) for dyspepsia
2. See Appendix A for Emetogenic Potential of Chemotherapy/Biotherapy Agents
3. Oral continuous dosing of chemotherapy/biotherapy for prolonged periods of time presents an emetogenic classification challenge as the emetogenic risk is likely overestimated in the product information. Therefore, an individualized approach is recommended and utilizing as needed antiemetics instead of routine premedication is often sufficient.
4. All SA are considered therapeutically equivalent when dosed appropriately, see Appendix C (ondansetron preferred)
BREAKTHROUGH NAUSEA AND VOMITING

General principles:
- SA and NKA generally not effective or approved for treatment of breakthrough nausea/vomiting
- Use antiemetic from another class the patient is not already taking
- Use of suppositories may be helpful if patient cannot take oral medication and IV access is not readily available; however, severity of condition may warrant IV antiemetics
- Instruct the patient to go to Emergency Center if not improving and/or not able to drink fluids

Patient able to tolerate PO

Patient experiences breakthrough nausea and vomiting

Patient not able to tolerate PO or has persistent nausea/vomiting with oral antiemetics

Choose an oral agent from a class not already given that Day:
- Phenothiazine or prokinetic agent
- If persistent nausea, give: short-acting SA, or atypical antipsychotic, or ABH combination product
- Consider adding steroids and/or benzodiazepine to other classes for synergy as tolerated

Choose an IV agent from a class not already given that Day:
- Phenothiazine or prokinetic agent (if not already given within 4 hours)
- Short-acting SA or high-dose prokinetic agent plus diphenhydramine
- Consider adding steroids and/or benzodiazepine to other classes for synergy as tolerated

Reassess patient prior to subsequent cycles (see Page 6)

1 Suppositories should not be used in patients with an absolute neutrophil count (ANC) less than 1.0 K/microliter and/or a platelet count less than 50 K/microliter
2 See Appendix C for medication dosing specifics
3 If patient responds, consider around-the-clock dosing of the agent to which they responded and re-evaluate appropriateness periodically during period of risk
4 ABH = Ativan® (lorazepam), Benadryl® (diphenhydramine), Haldol® (haloperidol)
Adult Antiemetic Management of Chemotherapy-Induced Nausea and Vomiting (CINV)

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

SUBSEQUENT CYCLES OF CHEMOTHERAPY

ASSESSMENT OF PRIOR CHEMOTHERAPY

For subsequent cycles of the same chemotherapy regimen, re-evaluate effectiveness of antiemetic regimen and side effects of antiemetic premedication

ANTIEMETIC RESPONSE

- Patient tolerated treatment with minimal nausea and no vomiting
  - No change in antiemetic regimen

- Patient tolerated treatment with minimal nausea and no vomiting, but had side effects due to antiemetics
  - Consider changes in dosing or other management strategies (i.e., other medications, non-pharmacologic measures)

- Patient had one or more episodes of vomiting in a 24 hour period or oral intake significantly decreased due to nausea
  - Consider any or all of the following:
    - Adding a benzodiazepine to the regimen
    - Adding an agent from a different class to the antiemetic regimen (see Appendix C)
    - Substituting high-dose intravenous metoclopramide (with diphenhydramine) for the SA

1 Changing to another SA after failing one has not been shown to be an effective strategy for management of breakthrough nausea and vomiting, although some individual patients have distinct preferences of one SA over another for prophylaxis

Department of Clinical Effectiveness V6
Approved by The Executive Committee of the Medical Staff on 01/29/2019

Copyright 2019 The University of Texas MD Anderson Cancer Center
APPENDIX A: Emetogenic Potential of Parenteral Chemotherapy/Biotherapy Agents – High and Moderate

<table>
<thead>
<tr>
<th>Risk Level</th>
<th>Frequency of Emesis (%)</th>
<th>Chemotherapy/Biotherapy Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>High</td>
<td>Greater than 90%</td>
<td>AC combination defined as either doxorubicin or epirubicin with cyclophosphamide</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Carboplatin(^1) (greater than or equal to AUC of 4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Carmustine (greater than 250 mg/m(^2))</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cisplatin(^1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cyclophosphamide (greater than 1,500 mg/m(^2))</td>
</tr>
<tr>
<td>Moderate</td>
<td>30% to 90%</td>
<td>Aldesleukin (greater than or equal to 12 million units/m(^2))</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Arsenic trioxide</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Azacitidine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bendamustine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Busulfan(^1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Carboplatin(^1) (less than AUC of 4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Carmustine (less than or equal to 250 mg/m(^2))</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clofarabine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cyclophosphamide (less than or equal to 1,500 mg/m(^2))</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cytarabine (greater than 200 mg/m(^2))</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dactinomycin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Daunorubicin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dinutuximab</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dacarbazine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Doxorubicin (greater than 50 mg/m(^2))</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Epirubicin (greater than 90 mg/m(^2))</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ifosfamide (high dose: greater than 2 grams/m(^2)/dose)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mechlorethamine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Streptozocin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Doxorubicin (less than or equal to 50 mg/m(^2))</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Epirubicin (less than or equal to 90 mg/m(^2))</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Idarubicin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ifosfamide (less than or equal to 2 grams/m(^2)/dose)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Interferon alpha (greater than or equal to 10 million units/m(^2)/dose)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Irinotecan</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Liposomal irinotecan</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Melphalan(^1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Methotrexate (greater than or equal to 250 mg/m(^2))</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oxaliplatin(^1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Temozolomide</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Trabectedin</td>
</tr>
</tbody>
</table>

\(^1\) Emetogenic risk may vary depending on the dosing, administration and/or concurrently administered chemotherapy

Continued on next page
## APPENDIX A Continued: Emetogenic Potential of Parenteral Chemotherapy/Biotherapy – Low and Minimal

<table>
<thead>
<tr>
<th>Risk Level</th>
<th>Frequency of Emesis (%)</th>
<th>Chemotherapy/Biotherapy Agents</th>
</tr>
</thead>
</table>
| **Low** | 10% to 30% | - Ado-trastuzumab emtansine
- Aldesleukin (less than 12 million units/m²/dose)
- Altretamine
- Belinostat
- Brentuximab Vedotin
- Cabazitaxel
- Carfilzomib
- Copanlisib
- Cytarabine (low dose: 100 – 200 mg/m²)
- Docetaxel
- Doxorubicin (liposomal)
- Eribulin
- Etoposide
- Floxuridine
- 5-Fluorouracil
- Gemcitabine
- Interferon Alpha (greater than 5 million but less than 10 million units/m²/dose)
- Ixabepilone
- Methotrexate (greater than 50 mg/m² but less than 250 mg/m²)
- Mitomycin
- Mitoxantrone |

| **Minimal** | Less than 10% | - Afiblercept (IV agent)
- Alectuzumab
- Asparaginase
- Atezolizumab
- Avelumab
- Axicabtagene ciloleucel (CAR-T)¹
- Bevacizumab
- Bleomycin
- Blinatumomab
- Bortezomib
- Cameplimab-rwlc
- Cetuximab
- Cladribine
- Cytarabine less than 100 mg/m²
- Daratumumab
- Decitabine
- Denileukin diftitox
- Durvalumab
- Elotuzumab
- Fludarabine
- Inotuzumab ozogamicin
- Interferon Alfa (less than or equal to 5 million units/m²/dose)
- Ipilimumab¹
- Liposomal vincristine
- Methotrexate (less than or equal to 50 mg/m²)
- Mogamulizumab-kpkc
- Moxetumomab pasudotox-tdfk
- Naloxone
- Nivolumab¹
- Obinutuzumab
- Ofatumumab
- Panitumumab
- Pegasparaginase
- Pembrolizumab¹
- Pertuzumab
- Ramucirumab
- Rituximab
- Siltuximab
- Temsirolimus
- Tisagenlecleucel (CAR-T)¹
- Trastuzumab
- Valrubicin
- Vinblastine
- Vincristine
- Vinorelbine |

*Not on MDACC Pharmacy Formulary as of November, 2018

¹ Immune therapy – use of steroids not recommended; see Appendix C for more details

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.
## APPENDIX A Continued: Emetogenic Potential of ORAL Chemotherapy/Biotherapy

Note: Oral continuous dosing of chemotherapy/biotherapy for prolonged periods of time presents an emetogenic classification challenge as the emetogenic risk is likely overestimated in the product information. Therefore, an individualized approach is recommended and utilizing as needed antiemetics instead of routine premedication is often sufficient.

<table>
<thead>
<tr>
<th>Emetogenic Risk</th>
<th>Chemotherapy/Biotherapy Agents</th>
</tr>
</thead>
</table>
| **High to Moderate** | ● Busulfan (greater than or equal to 4 mg/day)  
● Cyclophosphamide (greater than or equal to 100 mg/m²/dose)  
● Etoposide  
● Lomustine  
● Midostaurin*  
● Olaparib  
● Niraparib*  
● Procarbazine  
● Rucaparib  
● Temozolomide (greater than 75 mg/m²/dose) |

| **Low to Minimal** | ● Abemaciclib*  
● Acalabrutinib  
● Afatinib  
● Alectinib  
● Alretamine  
● Apalutamide*  
● Axitinib  
● Bexarotene  
● Binimetinib  
● Bosutinib*  
● Brigatinib  
● Busulfan (less than 4 mg/day)  
● Cabozantinib*  
● Capecitabine  
● Ceritinib  
● Chlorambucil  
● Cobimetinib*  
● Crizotinib  
● Cyclophosphamide (less than 100 mg/m²/dose)  
● Dabrafenib  
● Dacomitinib*  
● Dasatinib  
● Duvelisib*  
● Encorafenib  
● Erlotinib  
● Estramustine  
● Everolimus  
● Fludarabine  
● Gefitinib  
● Hydroxyurea  
● Ibrutinib  
● Ideclali*  
● Imatinib  
● Ivosidenib*  
● Ixazomib  
● Lapatinib  
● Lenalidomide  
● Lenvatinib*  
● Lorlatinib*  
● Melphalan  
● Mercaptopurine  
● Methotrexate  
● Neratinib maleate*  
● Nilotinib  
● Osimertinib  
● Palbociclib  
● Panobinostat  
● Pazopanib  
● Ponatinib*  
● Regorafenib  
● Ribociclib*  
● Ruxolitinib  
● Sonidegib*  
● Soraferinib  
● Sunitinib  
● Telazoparib*  
● Temozolomide (less than or equal to 75 mg/m²/dose)  
● Thioguanine  
● Topotecan  
● Trametinib  
● Trifluridine–tipiracil  
● Tretinoin  
● Vandetanib  
● Venetoclax  
● Vismodegib |

*Not on MDACC Pharmacy Formulary as of November, 2018

---

**Disclaimer:** This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.
### APPENDIX B: Antiemetic Regimens for Prevention of Acute and Delayed CINV

<table>
<thead>
<tr>
<th>Olanzapine/SA/Steroids/NKA - HEC, single day ONLY</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Olanzapine(^1) 10 mg PO daily on Days 1 – 4</td>
</tr>
<tr>
<td>Choose one from each category below:</td>
</tr>
<tr>
<td>• Serotonin antagonist(^2)</td>
</tr>
<tr>
<td>○ Granisetron 1 mg IV</td>
</tr>
<tr>
<td>○ Ondansetron 8 – 16 mg IV</td>
</tr>
<tr>
<td>○ Palonosetron 0.25 mg IV</td>
</tr>
<tr>
<td>• Steroids</td>
</tr>
<tr>
<td>○ Dexamethasone(^3,4) 12 mg IV on Day 1; then 8 mg PO once daily on Days 2 – 3</td>
</tr>
<tr>
<td>• Neurokinin-1 antagonist(^5)</td>
</tr>
<tr>
<td>○ Aprepitant 125 mg PO on Day 1; then 80 mg PO on Days 2 – 3</td>
</tr>
<tr>
<td>○ Fosaprepitant 150 mg IV</td>
</tr>
<tr>
<td>• PRN antiemetics at home</td>
</tr>
<tr>
<td>○ Prochlorperazine 5 – 10 mg PO every 6 hours prn nausea/vomiting</td>
</tr>
<tr>
<td>○ Ondansetron 8 mg PO every 12 hours prn nausea/vomiting (do not give SA at home if long-acting SA administered on Day 1)</td>
</tr>
</tbody>
</table>

---

\(^1\) Olanzapine 5 mg not as effective, but maybe practical if 10 mg not tolerated

\(^2\) All SAs are considered therapeutically equivalent when dosed appropriately, see Appendix C (ondansetron preferred)

\(^3\) The following features of steroids should be considered in patients with hematologic malignancies prior to prescribing them as part of the antiemetic regimen: a) risk of immunosuppression; b) avoid duplicative therapy, may already be part of chemotherapy regimen; c) inherent activity against hematologic malignancies may mask beneficial effects of chemotherapy in clinical trials. See Appendix C for other safety considerations.

\(^4\) Use of steroids is not recommended with immune and/or cellular therapies. See Appendix C for other safety considerations.

\(^5\) May interact with cytochrome P450 enzyme (CYP enzyme); check for drug interactions – see Appendix C
## APPENDIX B: Antiemetic Regimens for Prevention of Acute and Delayed CINV – continued from previous page

<table>
<thead>
<tr>
<th>Olanzapine/SA/Steroids - HEC or MEC, single day ONLY</th>
</tr>
</thead>
<tbody>
<tr>
<td>● Olanzapine(^1) 10 mg PO daily on Days 1 – 4</td>
</tr>
<tr>
<td>Choose one from each category below:</td>
</tr>
<tr>
<td>● Serotonin antagonist(^2)</td>
</tr>
<tr>
<td>○ Granisetron 1 mg IV</td>
</tr>
<tr>
<td>○ Ondansetron 8 – 16 mg IV</td>
</tr>
<tr>
<td>○ Palonosetron 0.25 mg IV</td>
</tr>
<tr>
<td>● Steroids</td>
</tr>
<tr>
<td>○ Dexamethasone(^3/4) 20 mg IV on Day 1; then 8 mg PO twice a day on Days 2 – 3</td>
</tr>
</tbody>
</table>

**PRN antiemetics at home**

- Prochlorperazine 5 – 10 mg PO every 6 hours prn nausea/vomiting
- Ondansetron 8 mg PO every 12 hours prn nausea/vomiting (do not give SA at home if long-acting SA administered on Day 1)

---

\(^1\) Olanzapine 5 mg not as effective, but maybe practical if 10 mg not tolerated

\(^2\) All SAs are considered therapeutically equivalent when dosed appropriately, see Appendix C (ondansetron preferred)

\(^3\) The following features of steroids should be considered in patients with hematologic malignancies prior to prescribing them as part of the antiemetic regimen: a) risk of immunosuppression; b) avoid duplicative therapy, may already be part of chemotherapy regimen; c) inherent activity against hematologic malignancies may mask beneficial effects of chemotherapy in clinical trials. See Appendix C for other safety considerations.

\(^4\) Use of steroids is not recommended with immune and/or cellular therapies. See Appendix C for other safety considerations.
## APPENDIX B: Antiemetic Regimens for Prevention of Acute and Delayed CINV – continued from previous page

### SA/Steroids/NKA: HEC or MEC, single or multi-day

Choose one from **each** category below:

- **Serotonin antagonist**
  - Granisetron
    - 1 mg IV (multi-day chemotherapy – repeat daily followed by PO at home for 2 - 3 days after chemotherapy completed)
    - 3.1 mcg/24 hour patch* (apply 24 – 48 hours prior to chemotherapy; sustained release over 7 days)
  - Ondansetron 8 – 16 mg IV (multi-day chemotherapy – repeat daily followed by PO at home for 2 – 3 days after chemotherapy completed)
  - Palonosetron 0.25 mg IV (multi-day chemotherapy – data is available to support daily or every other day dosing)

- **Steroids**
  - Dexamethasone2,3
    - If aprepitant/fosaprepitant: dexamethasone 12 mg IV on day 1; then 8 mg PO daily on Days 2 – 3
    - If rolapitant: dexamethasone 20 mg IV on Day 1; then 8 mg PO twice a day on Days 2 – 3
  - For non-cisplatin containing regimens consider steroid sparing options after completion of chemotherapy

- **Neurokinin-1 antagonist**
  - Aprepitant4 125 mg PO on day 1; then 80 mg PO on Days 2 and 3 (multi-day chemotherapy – may continue 80 mg daily while receiving chemotherapy and 2 days after completion)
  - Fosaprepitant4
    - 150 mg IV on day 1 only (single day chemotherapy – single dose lasts for 3 days; multi-day chemotherapy - may repeat dosing, but no sooner than 3 days)
  - Rolaipant* 180 mg PO on Day 1 only

**PRN antiemetics at home**

- Prochlorperazine 5 – 10 mg PO every 6 hours prn nausea/vomiting
- Ondansetron 8 mg PO every 12 hours prn nausea/vomiting (do not give SA at home if long-acting SA administered on Day 1)
- Consider scheduled short-acting SA for the first 2 - 3 days after chemotherapy (do not give SA at home if long-acting SA administered on Day 1)

* Restricted drug on MDACC Pharmacy Formulary as of November, 2018

---

1 All SAs are considered therapeutically equivalent when dosed appropriately, see Appendix C (ondansetron preferred)
2 The following features of steroids should be considered in patients with hematologic malignancies prior to prescribing them as part of the antiemetic regimen:
   a) risk of immunosuppression; b) avoid duplicative therapy, may already be part of chemotherapy regimen; c) inherent activity against hematologic malignancies may mask beneficial effects of chemotherapy in clinical trials. See Appendix C for other safety considerations.
3 Use of steroids is not recommended with immune and/or cellular therapies. See Appendix C for other safety considerations
4 May interact with cytochrome P450 enzyme (CYP enzyme); check for drug interactions – see Appendix C

---

*Continued on next page*
Adult Antiemetic Management of Chemotherapy-Induced Nausea and Vomiting (CINV)

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

APPENDIX B: Antiemetic Regimens for Prevention of Acute and Delayed CINV – continued from previous page

### SA/Steroids: MEC ONLY, single or multi-day

Choose one from **each** category below:

- **Serotonin antagonist**
  - Granisetron
    - 1 mg IV (multi-day chemotherapy – repeat daily followed by PO at home for 2 - 3 days after chemotherapy completed)
    - 3.1 mcg/24 hour patch* (apply 24 – 48 hours prior to chemotherapy; sustained release over 7 days)
  - Ondansetron 8 – 16 mg IV (multi-day chemotherapy – repeat daily followed by PO at home for 2 – 3 days after chemotherapy completed)
  - Palonosetron 0.25 mg IV (multi-day chemotherapy – data is available to support daily or every other day dosing)

- **Steroids**
  - Dexamethasone 2, 3 20 mg IV on Day 1; then 8 mg PO twice a day on Days 2 – 3
  - For some non-cisplatin containing regimens consider steroid sparing options after completion of chemotherapy

---

### PRN antiemetics at home

- Prochlorperazine 5 – 10 mg PO every 6 hours prn nausea/vomiting
- Ondansetron 8 mg PO every 12 hours prn nausea/vomiting (do not give SA at home if long-acting SA administered on Day 1)
- Consider scheduled short-acting SA for the first 2 – 3 days after chemotherapy (do not give SA at home if long-acting SA administered on Day 1)

---

*Restricted drug on MDACC Pharmacy Formulary as of November, 2018

1 All SAs are considered therapeutically equivalent when dosed appropriately, see Appendix C (ondansetron preferred)

2 The following features of steroids should be considered in patients with hematologic malignancies prior to prescribing them as part of the antiemetic regimen:
   a) risk of immunosuppression; b) avoid duplicative therapy, may already be part of chemotherapy regimen; c) inherent activity against hematologic malignancies may mask beneficial effects of chemotherapy in clinical trials. See Appendix C for other safety considerations.

3 Use of steroids is not recommended with immune and/or cellular therapies. See Appendix C for other safety considerations.
### APPENDIX C: Antiemetic Medication Options

<table>
<thead>
<tr>
<th>Medication</th>
<th>Adult Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anxiolytics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alprazolam (Xanax®)</td>
<td>0.5 – 2 mg PO every 6 hours</td>
<td>• <strong>Indication:</strong> anticipatory CINV (drug class of choice)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• <strong>Class adverse effects</strong>: sedation, dizziness, disorientation, hypotension, amnesia</td>
</tr>
<tr>
<td>Lorazepam (Ativan®)</td>
<td>0.5 – 2 mg PO, SL or IV every 6 hours</td>
<td>• Lorazepam SL is administered using the oral concentrate formulation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Exert caution when using in the elderly, as they may be more sensitive to the side effects (see Beers Criteria for more information)</td>
</tr>
<tr>
<td><strong>Atypical Antipsychotics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Olanzapine (Zyprexa®)</td>
<td>Prevention: 10 mg PO daily on Days 1 – 4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Breakthrough: 2.5 – 5 mg PO twice a day or 10 mg PO daily times 3 days</td>
<td>• <strong>Indication:</strong> prophylaxis for acute and delayed CINV (with a SA plus dexamethasone with or without an NKA)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Olanzapine 5 mg not as effective, but maybe practical if 10 mg not tolerated</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• <strong>Adverse effects</strong>: drowsiness, dizziness, hyperglycemia, restlessness, extrapyramidal symptoms,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Avoid concomitant use with metoclopramide and haloperidol due to increased risk of extrapyramidal reactions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• <strong>QTc prolongation</strong>: possible Torsade's de Pointes (TdP) - medication can cause QT prolongation but there is insufficient evidence that when used as directed in official labeling, the medication is associated with a risk of causing TdP</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Exert caution when using in the elderly, as they may be more sensitive to the side effects (see Beers Criteria for more information)</td>
</tr>
</tbody>
</table>

---

1 Adverse effects are not all inclusive, refer to package insert


3 For QTc prolongation information, see [www.Crediblemeds.org](http://www.Crediblemeds.org)
## APPENDIX C: Antiemetic Medication Options – continued from previous page

<table>
<thead>
<tr>
<th>Medication</th>
<th>Adult Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Butyrophenones</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haloperidol (Haldol®)</td>
<td>0.5 – 2 mg IV every 6 hours (see also ABH on Page 19)</td>
<td>• <strong>Indication:</strong> treatment of breakthrough CINV</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• <strong>Adverse effects</strong>: sedation, tachycardia, hypotension, restlessness, extrapyramidal symptoms (may co-administer with benzodiazepine or antihistamine to avoid this)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• <strong>QTc prolongation</strong>: known risk of TdP - medication causes QT interval prolongation and is clearly associated with a risk of TdP</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Exert caution when using in the elderly, as they may be more sensitive to the side effects (see Beers Criteria 3 for more information)</td>
</tr>
<tr>
<td><strong>Cannabinoids</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dronabinol (Marinol®)</td>
<td>2.5 – 10 mg PO either every 3 hours or every 6 hours</td>
<td>• <strong>Indication:</strong> prophylaxis for acute and delayed CINV refractory to other antiemetics</td>
</tr>
<tr>
<td>Nabilone (Cesamet®)*</td>
<td>1 – 2 mg PO twice a day</td>
<td>• <strong>Adverse effects</strong>: dizziness, somnolence, sleep disturbances, confusion, hallucinations</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Avoid abrupt discontinuation of therapy which may precipitate withdrawal</td>
</tr>
</tbody>
</table>

*Not on MDACC Pharmacy Formulary as of November, 2018

1 Adverse effects are not all inclusive, refer to package insert

2 For QTc prolongation information, see [www.Crediblemeds.org](http://www.Crediblemeds.org)


Continued on next page
APPENDIX C: Antiemetic Medication Options – continued from previous page

<table>
<thead>
<tr>
<th>Medication</th>
<th>Adult Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Neurokinin-1 Antagonists</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aprepitant (Emend®)</td>
<td>125 mg PO</td>
<td>80 mg PO daily for 2 days</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Indication:</strong> prophylaxis of acute and delayed CINV (with SA plus dexamethasone)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Class adverse effects</strong>¹: hiccups, fatigue, dizziness, diarrhea</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Decrease dexamethasone dose by 50% with concomitant use (same day) of aprepitant and fosaprepitant</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Drug interactions due to CYP3A4 inhibition for aprepitant and fosaprepitant; CYP2D6 with rolapitant</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Rolapitant has only been studied with single-day chemotherapy regimens</strong></td>
</tr>
<tr>
<td>Fosaprepitant (Emend® IV)</td>
<td>115 mg IV</td>
<td>Aprepitant 80 mg PO daily for 2 days</td>
</tr>
<tr>
<td></td>
<td>150 mg IV</td>
<td>None recommended (Note: See dosing with dexamethasone)</td>
</tr>
<tr>
<td>Rolapitant (Varubi®)*</td>
<td>180 mg PO</td>
<td>None recommended</td>
</tr>
</tbody>
</table>

| **Non-Phenothiazine Antihistamines** | | |
| Diphenhydramine (Benadryl®) | 12.5 – 50 mg PO or IV every 6 hours (may dose every 4 hours) | **Indication:** co-administered with other antiemetics to manage toxicity |
| | | **Adverse effects**²: sedation, dry mouth, blurred vision, agitation, paradoxical reactions (excitement) |
| | | Exert caution when using in the elderly, as they may be more sensitive to the side effects (see Beers Criteria² for more information) |

¹Adverse effects are not all inclusive, refer to package insert


*Restricted drug on MDACC Pharmacy Formulary as of November, 2018

Continued on next page
## Prokinetic Agents

<table>
<thead>
<tr>
<th>Medication</th>
<th>Adult Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metoclopramide (Reglan®)</td>
<td>• Standard dose 10 – 40 mg PO or IV every 6 hours (may dose every 4 hours)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• High dose 0.5 – 2 mg/kg IV with diphenhydramine 25 mg IV every 4 hours</td>
<td><em>Indication:</em> breakthrough CINV, prophylaxis of acute (high-dose only) and delayed (with steroids) CINV</td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>Adverse effects</em>: sedation, diarrhea, extrapyramidal symptoms (especially with high dose, may co-administer with benzodiazepine or antihistamine to avoid this), tremors, akathisia</td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>QTc prolongation</em>: Conditional risk of TdP - these drugs are associated with a risk of Tdp BUT only under certain conditions (e.g. excessive dose, hypokalemia, congenital long QT or by causing a drug-drug interaction that results in excessive QT interval prolongation)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exert caution when using in the elderly, as they may be more sensitive to the side effects (see Beers Criteria³ for more information)</td>
</tr>
</tbody>
</table>

³ Adverse effects are not all inclusive, refer to package insert

³² For QTc prolongation information, see [www.credibilitems.org](http://www.credibilitems.org)

### APPENDIX C: Antiemetic Medication Options – continued from previous page

<table>
<thead>
<tr>
<th>Medication</th>
<th>Adult Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Serotonin Antagonists (SA)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dolasetron (Anzemet®)*</td>
<td>100 – 200 mg PO</td>
<td>• <em>Indication</em>: prophylaxis of acute and delayed CINV</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Dolasetron available as oral tablet only. IV use is not recommended by FDA.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Apply granisetron patch 24 - 48 hours prior to chemotherapy administration</td>
</tr>
<tr>
<td></td>
<td>100 mg PO daily</td>
<td>• FDA has amended the product information of ondansetron to limit single intravenous doses to 16 mg</td>
</tr>
<tr>
<td>Granisetron Kytril® – IV/PO</td>
<td>1 – 2 mg PO or 1 mg IV</td>
<td>• Palonosetron: phase III clinical trials did not allow repeat dosing for 7 days. The optimal timing of repeat doses of palonosetron is currently unknown.</td>
</tr>
<tr>
<td></td>
<td>2 mg PO daily or 1 mg PO twice a day</td>
<td></td>
</tr>
<tr>
<td>Sancuso® – patch**</td>
<td>3.1 mg/24 hours patch (total dose delivered 34.3 mg/7 days)</td>
<td>• <strong>Class adverse effects</strong>: headache, constipation, fatigue</td>
</tr>
<tr>
<td>Ondansetron (Zofran®)</td>
<td>8 – 24 mg PO or 8 – 16 mg IV</td>
<td>• QTc prolongation**: increased risk of QTc prolongation has been observed with IV formulations of ondansetron, dolasetron, and granisetron</td>
</tr>
<tr>
<td>(preferred agent) Oral disintegrating tablet, tablet, oral solution, IV</td>
<td>8 mg PO twice a day or 16 mg PO daily or 8 mg IV twice a day</td>
<td>o Dolasetron and granisetron: possible risk of TdP – these medications can cause QT prolongation BUT there is insufficient evidence that when used as directed in official labeling, the medications are associated with a risk of causing TdP</td>
</tr>
<tr>
<td></td>
<td></td>
<td>o Ondansetron: known risk of TdP - medication causes QT interval prolongation and is clearly associated with a risk of TdP, consider EKG monitoring especially with doses greater than 16 mg per day</td>
</tr>
<tr>
<td>Palonosetron (Aloxi®)</td>
<td>0.25 mg IV</td>
<td>• <strong>Short-acting SAs include</strong>:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>o Dolasetron (all formulations)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>o Granisetron (IV/PO formulations)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>o Ondansetron (all formulations)</td>
</tr>
</tbody>
</table>

*Not on MDACC Pharmacy Formulary as of November, 2018
**Restricted drug on MDACC Pharmacy Formulary as of November, 2018
1Adverse effects are not all inclusive, refer to package insert.
2For QTc prolongation information, see [www.Crediblemeds.org](http://www.Crediblemeds.org)

Continued on next page
## Antiemetic Medication Options – continued from previous page

<table>
<thead>
<tr>
<th>Medication</th>
<th>Adult Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steroids</td>
<td>ACUTE (before)</td>
<td>DELAYED</td>
</tr>
</tbody>
</table>
| Dexamethasone (Decadron®) | Day 1: 10 – 20 mg PO or IV | Days 2 – 4 (or longer): 4 – 8 mg PO or IV twice daily | **Indication:** prophylaxis of acute and delayed CINV  
When administered with aprepitant/fosaprepitant, dexamethasone dose should be decreased to 12 mg instead of 20 mg  
Caution in patients with hematologic malignancies  
Use of steroids is not recommended with immune and/or cellular therapies  
A steroid sparing prophylactic antiemetic regimen is preferred when:  
○ Immune checkpoint inhibitors are administered alone, as these are low emetogenic risk and alternative antiemetics should be considered  
○ Immune checkpoint inhibitors are administered concurrently with moderate-high emetogenic risk chemotherapy due to potential for negative impact on cancer outcomes  
○ Cellular therapies, including lymphodepleting chemotherapy preparative regimens, as the risk of inactivating the immune response is very high with even small doses of steroids. Avoiding the use of steroids for 3 - 5 days prior to and 90 days after cell administration is optimal.  
**Class adverse effects:** hyperglycemia, insomnia, hiccups, dyspepsia, agitation, weight gain, hypertension  
○ Increased risk of infection with prolonged use greater than 2 weeks |
| Dexamethasone with either aprepitant 125 mg PO or fosaprepitant 115 mg IV | 12 mg PO or IV | 8 mg PO daily for 3 days |
| Dexamethasone with fosaprepitant 150 mg IV | 12 mg PO or IV | Day 2: 8 mg PO daily  
Days 3 - 4: 8 mg PO twice daily |

1 The following features of steroids should be considered in patient with hematologic malignancies prior to prescribing them as part of the antiemetic regimen: a) risk of immunosuppression; b) avoid duplicative therapy, may already be part of chemotherapy regimen; c) inherent activity against hematologic malignancies may mask beneficial effects of chemotherapy in clinical trials  
2 Use of steroids is not recommended with immune and/or cellular therapies  
3 Adverse effects are not all inclusive, refer to package insert
## APPENDIX C: Antiemetic Medication Options – continued from previous page

<table>
<thead>
<tr>
<th>Medication</th>
<th>Adult Dosage</th>
<th>Comments</th>
</tr>
</thead>
</table>
| ABH capsules:  
- Lorazepam 0.34 mg  
- Diphenhydramine 25 mg  
- Haloperidol 1.5 mg | 1 capsule PO every 6 hours |  
- **Indication:** treatment of breakthrough CINV; prophylaxis of delayed CINV (refractory to other antiemetics)  
- Adverse effects as per individual agents  
- Additive amounts are not equal between the routes of administration due to absorption variances  
- QTc prolongation²: known risk of TdP - medication causes QT interval prolongation and is clearly associated with a risk of TdP (haloperidol)  
- Exert caution when using in the elderly, as they may be more sensitive to the side effects (see Beers Criteria³ for more information) |
| ABH suppositories¹:  
- Lorazepam 1 mg  
- Diphenhydramine 12.5 mg  
- Haloperidol 2 mg | 1 suppository¹ PR every 6 hours |  
- Indication: treatment of breakthrough CINV; prophylaxis of delayed CINV (refractory to other antiemetics)  
- Adverse effects as per individual agents  
- Additive amounts are not equal between the routes of administration due to absorption variances  
- QTc prolongation²: known risk of TdP - medication causes QT interval prolongation and is clearly associated with a risk of TdP (haloperidol)  
- Exert caution when using in the elderly, as they may be more sensitive to the side effects (see Beers Criteria³ for more information) |
| ABH IV:  
- Lorazepam 0.5 mg  
- Diphenhydramine 12.5 – 25 mg  
- Haloperidol 0.5 – 1 mg | Given as combination IV every 6 hours (need to order each agent separately) |  
- Indication: treatment of breakthrough CINV; prophylaxis of delayed CINV (refractory to other antiemetics)  
- Adverse effects as per individual agents  
- Additive amounts are not equal between the routes of administration due to absorption variances  
- QTc prolongation²: known risk of TdP - medication causes QT interval prolongation and is clearly associated with a risk of TdP (haloperidol)  
- Exert caution when using in the elderly, as they may be more sensitive to the side effects (see Beers Criteria³ for more information) |

¹Suppositories should not be used in patients with an absolute neutrophil count (ANC) less than 1.0 K/microliter and/or a platelet count less than 50 K/microliter

²For QTc prolongation information, see [www.Crediblemeds.org](http://www.Crediblemeds.org)

SUGGESTED READINGS


DEVELOPMENT CREDITS

This practice consensus statement is based on majority opinion of the Nausea and Vomiting workgroup at the University of Texas MD Anderson Cancer Center for the patient population. These experts included:

Naifa L. Busaidy, MD (Endocrine Neoplasia and HD)  
Diana Cauley, PharmD (Pharmacy Clinical Programs)  
Ariel A. Callanta RN (Nursing)  
Cathy Eng, MD (GI Medical Oncology)  
Suzanne Gettys, PharmD (Pharmacy Clinical Programs)  
Alison Gulbis, PharmD (Pharmacy Clinical Programs)  
Sandra Horowitz, PharmD (Pharmacy Clinical Programs)  
Pauline Koinis, BSMT  
JoAnn Lim, PharmD (Pharmacy Clinical Programs)

Debbie McCue, PharmD (Pharmacy Clinical Programs)  
Laura Michaud, PharmD (Pharmacy Clinical Programs)  
Loven Panes, RN (Nursing)  
Demetrios Petropoulos, MD (Pediatrics – Patient Care)  
Eden Mae Rodriguez, PharmD (Pharmacy Clinical Programs)  
Jane Rogers, PharmD (Pharmacy Clinical Programs)  
Van Anh Trinh, PharmD (Pharmacy Clinical Programs)  
Laura Whited, PharmD (Pharmacy Clinical Programs)

†Core Development Team  
*Clinical Effectiveness Development Team